Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fluvirin FDA Manufacturing Inspections Expected By July

This article was originally published in The Pink Sheet Daily

Executive Summary

Positive outcome of FDA inspections this summer would be final barrier to re-introducing Fluvirin to the U.S. market. Earlier suspension by U.K. health authorities will not dampen demand for vaccine, Chiron says; the company expects to manufacture 25 mil.-30 mil. doses for 2005/2006 flu season.

You may also be interested in...



Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension

The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.

Chiron, GSK Flu Vaccine Availability May Not Be Clear Until August, CDC Says

Due to uncertainty about the number of vaccine suppliers, the agency has devised an immunization strategy based on three supply scenarios for the 2005-2006 influenza season. The strategy places individuals into tiers based upon their age, health status and contact with persons at high risk.

Chiron, GSK Flu Vaccine Availability May Not Be Clear Until August, CDC Says

Due to uncertainty about the number of vaccine suppliers, the agency has devised an immunization strategy based on three supply scenarios for the 2005-2006 influenza season. The strategy places individuals into tiers based upon their age, health status and contact with persons at high risk.

Related Content

Topics

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel